Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.

Other

Novex Talalmanyfejleszto Es Ertekesito Kulkereskedelmi Rt.

Peter Szentmiklosi

Zoltan Meszaros

Istvan Hermecz

Agnes Horvath

Sandor Virag

Jozsef Knoll

Agoston David

Lelle V Vasvari Nee Debreczy

Tamas Szuts

Gabor Kovacs

Attila Mandi

Gabor Nagy

Gabor Bernath

Istvan Racz

Ferenc Fulop

Sandor Makleit

Rezso Bognar

Jeno Marton

Jozsef Lengyel

Zsuzsanna Furst

Gyula Valovics

Sandor J Nagy

Janos Plachy

Laszlo Tardos

Katalin Marmarosi Nee Kellner

Gabor Horvath

Lelle Vasvari

Gyorgy Hidasi

Klara Gyires

Jozsef Nemes

Peter Sarkozi

Laszlo Szlavik

Eniko Schreiner Nee Kovats

Ilona Erdelyi

Laszlo Szavik

Josef Knoll

Erzsebet Babos Nee Vajas

Laszlo Gyarmati

Istvan Hermes

Geza Kerszturi

Jozse Knoll

Istvan Hurmecz

Laszo Tardos

Lelle Vasvari (nee Debreczy)

Katalin Marmarosi (nee Kellner)

Istvan Juhasz

The invention relates to novel stable aqueous primycin solutions containing 0.5 to 1.75% by mass/volume of primycin sulfate or 2.5 to 9% by mass/volume of a complex of primycin N-methylpyrrolidone and 2 to 15% by mass/volume of pyroglutamic acid, preferably L-pyroglutamic acid or a soluble salt, preferably the sodium salt thereof as calculated for the volume of the solution to be prepared and 40 to 60% by volume of isopropanol as calculated for the volume of the solution to be prepared as well as water in an amount adding up to 100%. The stable, aqueous primycin solutions are topical antibiotics.

Stable aqueous solutions of prymicin and pharmaceutical and cosmetic

This invention relates to a primycin-containing colloidal basic gel comprising 5-30% of primycin and 95-70% of N-methyl-pyrrolidone-2. The invention also relates to antibacterial compositions particularly for the treatment of acne vulgaris comprising as active ingredient 0.1-100% of a primycin-containing colloidal basic gel, if desired together with further antimicrobial active ingredients, in admixture with 99.9-0% of usual inert pharmaceutical filling, diluting and other formulating additives. The invention also relates to combination composition comprising as active ingredient 1-60% of a primycin-containing colloidal basic gel and 0.1-40% of further pharmaceutical active ingredient(s), e.g. one or more antibiotic(s), chemotherapeutical agent(s), fungistatic or fungicidal agent(s), steroidal or non-steroidal antiinflammatory agent (s), epithelogenic agent(s), local anaesthetic(s), and/or vitamin(s).

Primycin-containing colloidal basic gel

Proceeding for the production of pharmaceutical preparations of high

A new method of treatment is disclosed for a vascular obstructive lesion resulting from restricted blood circulation, characterized by an erythrocyte pathology, in an effected animal subject. The new method involves the administration of 1-(3',4'-diethoxybenzyl)-6,7-diethoxy-3,4-dihydroisoquinolinium-theophylli ne-7-acetat e, in a dosage and at a rate sufficient to maintain a blood concentration of at least 0.5 to at most 3 .gamma./ml, calculated on the basis of 1-(3',4'-diethoxybenzyl)-6,7-diethoxy-3,4-dihydroisoquinoline.

Method of treating a vascular obstructive lesion resulting from

N,N,N-trimethyl-2-hydroxyethyl-ammonium-[1-ethyl-6-fluoro-4-oxo-7-(1-pipera zinyl)-1,4-dihydro-quinolizine-3-carboxylate] of the formula I ##STR1## as a norfloxacin antimicrobial salt capable of enteral administration.

Medicinal norfloxacin salts

The invention relates to a process for the restoration and prevention of gastrointestinal injuries, which comprises treating a patient with an effective dose of racemic or optically active 1,6-dimethyl-4-oxo-1,6,7,8,9,9a-hexahydro-4H-pyrimido[1,2-a]pyrimidine-3-c arboxamide.

Treating process

New compounds of the following formula are disclosed:

Condensed pyrimidines

New optionally racemic or optically active pyrimido(1,2a) heterocyclic compounds of the formula ##STR1## wherein m is 0, 1 or 2,

Antiphlogistic and anticoagulant condensed pyrimidine derivatives

Compounds of the formula ##STR1## or pharmaceutically acceptable acid-addition or quaternart ammonium salts thereof

Pyrido[1,2-A]pyrimidine derivatives and method of analgesic treatment

Compounds of the formula: ##STR1## or pharmaceutically acceptable acid addition or quaternary ammonium salts thereof wherein

Pyrido[1,2-a]pyrimidine derivatives

The present invention relates to a solid oral pharmaceutical preparation with protracted release of the active ingredient consisting of discrete solid granules containing the active ingredient soluble in the stomach and auxiliary agents and of an equally solid external phase surrounding the said granules, whereby the granules forming the internal phase consist of granules prepared from a powder mixture which contains as active ingredient, or in addition to it a non-toxic metal compound, being capable of binding an acid, and being insoluble or but slightly soluble in neutral aqueous medium--particularly bismuth, aluminium or magnesium compound--and auxiliary materials prepared with an aqueous emulsion containing a hydrophobic component and hydrophylic emulsifiers, and the external phase contains a solid, dry, amphoteric gel forming substance in an amount of 1-50 percent w/w related to the total weight of the preparation in admixture with auxiliary agents. The preparation is produced by the wetting of the powder mixture containing the basic metal compound, auxiliary material and in given case additional active ingredient with the aqueous emulsion of the hydrophobic component prepared by applying the hydrophylic emulsifiers then by granulation and admixing the dried granules with the amphoteric gel forming substance, and pressing it into tablets, or filling into capsules.

Solid oral pharmaceutical product with increased efficacy and

1-Benzal-1,2,3,4-tetrahydro-isoquinolinium-theophylline-7-acetates are used in the manufacture of geriatric compositions.

1-Benzal-1,2,3,4-tetrahydro-isoquinolinium-theophylline-7-acetates

Pharmaceutical compositions of synergistic analgesic activity are provided which comprise an azido compound of the following formula: ##STR1## or a salt thereof wherein R is hydrogen, methyl, ethyl, acetyl or morpholino-methyl and a compound of the formula: ##STR2## wherein R.sup.1, R.sup.2, R.sup.3 are hydrogen or lower alkyl and the dotted lines represent hydrogenated bonds or olefinic bonds and pharmaceutically acceptable salts and quaternary salts thereof, in admixture with suitable inert solid or liquid carriers or dilutents.

Pharmaceutical composition having synergistic analgesic activity

An analgesic substitute for morphine comprising the synergistic combination of azidomorphine or azidocodeine with a pyrimidazolium.

Growing community of inventors

Budapest, Hungary

Peter Szentmiklosi